GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S.
RNS Number : 4604H MaxCyte, Inc. 03 August 2021 MaxCyte Announces Closing of Offering and Resulting Total Voting Rights This announcement contains inside information GAITHERSBURG, MD , August 3, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company
RNS Number : 1620H MaxCyte, Inc. 02 August 2021 MaxCyte Announces Full Exercise of Over-Allotment Option This announcement contains inside information GAITHERSBURG, MD , August 2, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT) (LSE: MXCT, MXCN) (" MaxCyte " or the " Company "), a leading
RNS Number : 1359H MaxCyte, Inc. 30 July 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 1349H MaxCyte, Inc. 30 July 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered
RNS Number : 0400H MaxCyte, Inc. 30 July 2021 MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market This announcement contains inside information GAITHERSBURG, MD , July 29, 2021 - MaxCyte, Inc.
This announcement contains inside information GAITHERSBURG, Md. , July 29, 2021 /PRNewswire/ -- MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial
RNS Number : 4538G MaxCyte, Inc. 26 July 2021 MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market This announcement contains inside information GAITHERSBURG, MD , July 26, 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform
RNS Number : 6950F MaxCyte, Inc. 19 July 2021 Termination of depositary interest facility and transition to CREST depository interests GAITHERSBURG, MD , 19 July 2021 - MaxCyte, Inc. (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announces certain
RNS Number : 8366E MaxCyte, Inc. 12 July 2021 Financial information in the Form S-1 registration statement & Change to Board of Directors GAITHERSBURG, MD , 12 July 2021 - MaxCyte, Inc. , (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering ("
